Joachim G.J.V. Aerts

30.5k total citations · 5 hit papers
341 papers, 10.6k citations indexed

About

Joachim G.J.V. Aerts is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Joachim G.J.V. Aerts has authored 341 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 235 papers in Pulmonary and Respiratory Medicine, 178 papers in Oncology and 55 papers in Immunology. Recurrent topics in Joachim G.J.V. Aerts's work include Lung Cancer Treatments and Mutations (95 papers), Cancer Immunotherapy and Biomarkers (92 papers) and Occupational and environmental lung diseases (64 papers). Joachim G.J.V. Aerts is often cited by papers focused on Lung Cancer Treatments and Mutations (95 papers), Cancer Immunotherapy and Biomarkers (92 papers) and Occupational and environmental lung diseases (64 papers). Joachim G.J.V. Aerts collaborates with scholars based in Netherlands, United States and Italy. Joachim G.J.V. Aerts's co-authors include Joost P. Hegmans, Henk C. Hoogsteden, Rudi W. Hendriks, Robin Cornelissen, Paul Baas, Daphne W. Dumoulin, Heleen Vroman, Dean A. Fennell, Koen Bezemer and Cor van der Leest and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joachim G.J.V. Aerts

328 papers receiving 10.5k citations

Hit Papers

Effect of Pembrolizumab After Stereot... 2010 2026 2015 2020 2019 2010 2016 2020 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
    2019 651 citations Joachim G.J.V. Aerts, Daphne W. Dumoulin et al. profile →
  2. Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
    2010 614 citations Joachim G.J.V. Aerts, Henk C. Hoogsteden et al. profile →
  3. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
  4. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
    2020 353 citations Joachim G.J.V. Aerts et al. profile →
  5. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
    2017 304 citations Joachim G.J.V. Aerts et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joachim G.J.V. Aerts Netherlands 53 5.5k 4.9k 2.0k 2.0k 1.0k 341 10.6k
Edward B. Garon United States 50 7.9k 1.4× 11.1k 2.3× 2.6k 1.3× 2.6k 1.3× 2.1k 2.1× 333 14.8k
Arnaud Scherpereel France 49 5.1k 0.9× 2.2k 0.5× 1.4k 0.7× 1.0k 0.5× 462 0.5× 212 8.3k
Bruno Vincenzi Italy 55 3.2k 0.6× 6.2k 1.3× 839 0.4× 2.6k 1.3× 2.0k 2.0× 428 11.0k
Vincent Launay‐Vacher France 40 4.8k 0.9× 10.6k 2.2× 4.4k 2.2× 2.5k 1.3× 1.2k 1.2× 158 16.3k
Marco Alifano France 52 3.8k 0.7× 4.4k 0.9× 3.1k 1.5× 2.1k 1.1× 1.4k 1.4× 283 11.0k
Gilbert Deray France 24 4.0k 0.7× 9.8k 2.0× 4.3k 2.1× 2.2k 1.1× 1.1k 1.1× 115 13.3k
Ichiro Yoshino Japan 56 6.2k 1.1× 3.1k 0.6× 1.7k 0.8× 2.0k 1.0× 822 0.8× 479 11.0k
Takashi Nakano Japan 45 4.4k 0.8× 2.2k 0.5× 688 0.3× 1.5k 0.7× 791 0.8× 456 8.8k
Stefan Sleijfer Netherlands 61 4.7k 0.9× 7.1k 1.5× 1.5k 0.7× 4.2k 2.1× 3.5k 3.5× 379 13.6k
Andreas Engert Germany 72 3.3k 0.6× 9.2k 1.9× 4.1k 2.0× 2.2k 1.1× 674 0.7× 552 20.7k

Countries citing papers authored by Joachim G.J.V. Aerts

Since Specialization
Citations

This map shows the geographic impact of Joachim G.J.V. Aerts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim G.J.V. Aerts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim G.J.V. Aerts more than expected).

Fields of papers citing papers by Joachim G.J.V. Aerts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim G.J.V. Aerts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim G.J.V. Aerts. The network helps show where Joachim G.J.V. Aerts may publish in the future.

Co-authorship network of co-authors of Joachim G.J.V. Aerts

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim G.J.V. Aerts. A scholar is included among the top collaborators of Joachim G.J.V. Aerts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim G.J.V. Aerts. Joachim G.J.V. Aerts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berg, Marijn, Lisette Krabbendam, Menno van Nimwegen, et al.. (2025). Evidence for altered immune-structural cell crosstalk in cystic fibrosis revealed by single cell transcriptomics. Journal of Cystic Fibrosis. 24(5). 849–860. 1 indexed citations
2.
Welters, Marij J.P., Saskia J. Santegoets, Nikki M. Loof, et al.. (2025). TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study. Nature Communications. 16(1). 4958–4958. 4 indexed citations
3.
4.
Bischoff, Erik, Job F. M. van Boven, Job van der Palen, et al.. (2025). Adherence to Inhaled Medication Guidelines in Patients with COPD: Evaluating the GOLD 2023 Strategy in a Real-World Secondary Care Setting. International Journal of COPD. Volume 20. 3877–3891.
5.
Bos, Daniël, et al.. (2024). Validation of a commercially available CAD-system for lung nodule detection and characterization using CT-scans. European Radiology. 35(2). 1076–1088. 3 indexed citations
6.
Willemsen, Marcella, Koen Bezemer, Sjoerd H. van der Burg, et al.. (2024). Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer. Journal of Clinical Oncology. 42(26). 3083–3093. 18 indexed citations
7.
Zhang, Zhen, Anne‐Marie C. Dingemans, Joachim G.J.V. Aerts, et al.. (2023). Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer. 183. 142–151. 16 indexed citations
8.
Hoek, Rogier A.S., Leonard Seghers, Catharina C. Moor, et al.. (2022). Diagnostic performance of electronic nose technology in chronic lung allograft dysfunction. The Journal of Heart and Lung Transplantation. 42(2). 236–245. 6 indexed citations
9.
Stingl, Christoph, Sai Ping Lau, Sjoerd H. van der Burg, et al.. (2022). Dataset from a proteomics analysis of tumor antigens shared between an allogenic tumor cell lysate vaccine and pancreatic tumor tissue.. Data in Brief. 44. 108490–108490. 2 indexed citations
10.
Brugge, Simone van der Sar–van der, et al.. (2021). Do-not-intubate status and COVID-19 mortality in patients admitted to Dutch non-ICU wards. European Journal of Clinical Microbiology & Infectious Diseases. 40(10). 2207–2209. 7 indexed citations
11.
Dumoulin, Daphne W., Robin Cornelissen, Koen Bezemer, Sara J. Baart, & Joachim G.J.V. Aerts. (2021). Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. Vaccines. 9(5). 525–525. 14 indexed citations
12.
Simons, Martijn, Valesca P. Retèl, Bram Ramaekers, et al.. (2021). Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. PharmacoEconomics. 39(12). 1429–1442. 17 indexed citations
13.
With, Mirjam de, Daan P. Hurkmans, Esther Oomen‐de Hoop, et al.. (2021). Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers. 13(6). 1370–1370. 9 indexed citations
14.
Muller, Mirte, Karlijn Hummelink, Daan P. Hurkmans, et al.. (2020). A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors. Clinical Cancer Research. 26(19). 5188–5197. 17 indexed citations
15.
Goeje, Pauline L. de, Koen Bezemer, Margaretha E.H. Kaijen-Lambers, et al.. (2019). Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients. Clinical Cancer Research. 25(7). 2219–2227. 40 indexed citations
16.
Dammeijer, Floris, Lysanne A. Lievense, Menno van Nimwegen, et al.. (2017). Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. Cancer Immunology Research. 5(7). 535–546. 123 indexed citations
17.
Aerts, Joachim G.J.V., Pauline L. de Goeje, Robin Cornelissen, et al.. (2017). Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research. 24(4). 766–776. 71 indexed citations
18.
Reck, Martin, Alexander Luft, Aleksandra Szczęsna, et al.. (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 34(31). 3740–3748. 397 indexed citations breakdown →
19.
VanDuijn, Martijn M., Christoph Stingl, Lennard J. M. Dekker, et al.. (2016). Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status. Cancer Immunology Research. 4(2). 165–172. 4 indexed citations
20.
Hegmans, Joost P., Joris D. Veltman, Margaretha Lambers, et al.. (2010). Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma. American Journal of Respiratory and Critical Care Medicine. 181(12). 1383–1390. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward B. Garon Breakdown of academic impact, for papers by Arnaud Scherpereel Breakdown of academic impact, for papers by Bruno Vincenzi Breakdown of academic impact, for papers by Vincent Launay‐Vacher Breakdown of academic impact, for papers by Marco Alifano Breakdown of academic impact, for papers by Gilbert Deray Breakdown of academic impact, for papers by Ichiro Yoshino Breakdown of academic impact, for papers by Takashi Nakano Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Andreas Engert
Rankless by CCL
2026